Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 3/20 | 0.51 |
| ▸ | TAS2R14 | Q9NYV8 | 9/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | HTR2C | P28335 | 3/20 | 0.40 |
| ▸ | HTR7 | P34969 | 3/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | CTSE | P14091 | 1/20 | 0.40 |
| ▸ | PGC | P20142 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2584515 | 0.85 | BACE1 (0.51) | LMNABACE1MAPK1 | |
| SCHEMBL2582413 | 0.81 | SPPL2A (0.52) | TAS2R14LMNACNR1CTSD | |
| SCHEMBL6477686 | 0.81 | CTSD (0.51) | PTGESLMNACNR1CTSDCTSE | |
| SCHEMBL2587456 | 0.80 | CA12 (0.48) | TAS2R14CNR2BACE1 | |
| SCHEMBL2578820 | 0.79 | RXFP1 (0.45) | TAS2R14CNR2BACE1 | |
| SCHEMBL2576474 | 0.79 | RORC (0.44) | TAS2R14CNR2BACE1 | |
| SCHEMBL7959979 | 0.79 | RORC (0.44) | TAS2R14CNR2BACE1 | |
| SCHEMBL7959974 | 0.79 | RORC (0.44) | TAS2R14CNR2BACE1 | |
| SCHEMBL6764842 | 0.76 | SPPL2A (0.53) | TAS2R14LMNACNR1CTSDBACE1 | |
| SCHEMBL6708204 | 0.75 | SPPL2A (0.50) | TAS2R14CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43802-E1 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2012-11-13 | — | — | US | claimed |
| US-RE42889-E1 | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2011-11-01 | — | — | US | claimed |
| US-20040229922-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. | 2004-11-18 | — | — | US | claimed |
| US-20040044047-A1 | Alpha and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. | 2004-03-04 | — | — | US | claimed |
| US-20030191319-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. | 2003-10-09 | — | — | US | claimed |
| US-6455581-B1 | INHIBITORS OF HIV PROTEASE. | G.D. SEARLE & CO. | 2002-09-24 | — | — | US | claimed |
| EP-0810209-B1 | Alpha - and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | SEARLE & CO (US) | 2002-06-05 | — | — | EP | claimed |
| EP-0810209-A2 | Alpha - and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1997-12-03 | — | — | EP | claimed |
| WO-1995006030-A1 | HYDROXYETHYLAMINO SULPHONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-03-02 | — | — | WO | claimed |
| EP-0810209-B1 | Alpha - and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | SEARLE & CO (US) | 2002-06-05 | — | — | EP | disclosed |
| EP-0810209-A2 | Alpha - and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1997-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191319-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, ASPH, PREP | PTGES 2316/4885TAS2R14 4157/4885LMNA 2536/4885 |
| US-20040044047-A1 | Alpha and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, PREP, ANPEP | PTGES 2177/4885TAS2R14 4129/4885LMNA 2567/4885 |
| US-20040229922-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, ASPH, PREP | PTGES 2316/4885TAS2R14 4157/4885LMNA 2536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.